|
Active Substance |
apalutamide |
|
Holder |
Janssen-Cilag NV |
|
Status |
Closed |
|
Indication |
in combination with androgen deprivation therapy (ADT) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) |
|
Public documents |
|
|
Last update |
31/08/2021 |
Erleada
Last updated on 13/09/2024